BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 25855759)

  • 1. The ever-evolving landscape of candidaemia in patients with acute leukaemia: non-susceptibility to caspofungin and multidrug resistance are associated with increased mortality.
    Wang E; Farmakiotis D; Yang D; McCue DA; Kantarjian HM; Kontoyiannis DP; Mathisen MS
    J Antimicrob Chemother; 2015 Aug; 70(8):2362-8. PubMed ID: 25855759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Candida species distribution and antifungal susceptibility testing according to European Committee on Antimicrobial Susceptibility Testing and new vs. old Clinical and Laboratory Standards Institute clinical breakpoints: a 6-year prospective candidaemia survey from the fungal infection network of Switzerland.
    Orasch C; Marchetti O; Garbino J; Schrenzel J; Zimmerli S; Mühlethaler K; Pfyffer G; Ruef C; Fehr J; Zbinden R; Calandra T; Bille J;
    Clin Microbiol Infect; 2014 Jul; 20(7):698-705. PubMed ID: 24188136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changing epidemiology of candidaemia in Australia.
    Chapman B; Slavin M; Marriott D; Halliday C; Kidd S; Arthur I; Bak N; Heath CH; Kennedy K; Morrissey CO; Sorrell TC; van Hal S; Keighley C; Goeman E; Underwood N; Hajkowicz K; Hofmeyr A; Leung M; Macesic N; Botes J; Blyth C; Cooley L; George CR; Kalukottege P; Kesson A; McMullan B; Baird R; Robson J; Korman TM; Pendle S; Weeks K; Liu E; Cheong E; Chen S;
    J Antimicrob Chemother; 2017 Apr; 72(4):1103-1108. PubMed ID: 28364558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical manifestations of candidemia caused by uncommon Candida species and antifungal susceptibility of the isolates in a regional hospital in Taiwan, 2007-2014.
    Liu WL; Lai CC; Li MC; Wu CJ; Ko WC; Hung YL; Tang HJ; Hsueh PR
    J Microbiol Immunol Infect; 2019 Aug; 52(4):612-619. PubMed ID: 28886952
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of initial antifungal therapy on mortality among patients with bloodstream infections with different Candida species and resistance to antifungal agents: A multicentre observational study by the Turkish Fungal Infections Study Group.
    Doğan Ö; Yeşilkaya A; Menekşe Ş; Güler Ö; Karakoç Ç; Çınar G; Kapmaz M; Aydın M; Keske Ş; Şahin S; Hacıseyitoğlu D; Yalçın D; Tekin S; Ataç N; Albayrak Ö; Aksu ED; Can F; Ergönül Ö
    Int J Antimicrob Agents; 2020 Jul; 56(1):105992. PubMed ID: 32335275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA; Messer SA; Moet GJ; Jones RN; Castanheira M
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Prevalence of Candida parapsilosis, C. orthopsilosis and C. metapsilosis in candidemia over a 5-year period at Nantes hospital and in vitro susceptibility to three echinocandins by E-test®].
    Thierry G; Morio F; Le Pape P; Gay-Andrieu F; Barre O; Miegeville M
    Pathol Biol (Paris); 2011 Feb; 59(1):52-6. PubMed ID: 20832195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative effectiveness of echinocandins versus fluconazole therapy for the treatment of adult candidaemia due to Candida parapsilosis: a retrospective observational cohort study of the Mycoses Study Group (MSG-12).
    Chiotos K; Vendetti N; Zaoutis TE; Baddley J; Ostrosky-Zeichner L; Pappas P; Fisher BT
    J Antimicrob Chemother; 2016 Dec; 71(12):3536-3539. PubMed ID: 27494929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidemiology, risk factor, species distribution, antifungal resistance and outcome of Candidemia at a single French hospital: a 7-year study.
    Tadec L; Talarmin JP; Gastinne T; Bretonnière C; Miegeville M; Le Pape P; Morio F
    Mycoses; 2016 May; 59(5):296-303. PubMed ID: 26806101
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients.
    Lortholary O; Desnos-Ollivier M; Sitbon K; Fontanet A; Bretagne S; Dromer F;
    Antimicrob Agents Chemother; 2011 Feb; 55(2):532-8. PubMed ID: 21078946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Echinocandin Susceptibility Profile of Fluconazole Resistant Candida Species Isolated from Blood Stream Infections.
    Deorukhkar SC; Saini S
    Infect Disord Drug Targets; 2016; 16(1):63-8. PubMed ID: 26648186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
    Sipsas NV; Lewis RE; Raad II; Kontoyiannis DP
    Int J Antimicrob Agents; 2009 Jul; 34(1):95-8. PubMed ID: 19251404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility and clinical outcomes of Candida parapsilosis bloodstream infections in a tertiary teaching hospital in Northern Taiwan.
    Lin CC; Liu CP; Hsieh FC; Lee CM; Wang WS
    J Microbiol Immunol Infect; 2015 Oct; 48(5):552-8. PubMed ID: 25315213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antifungal susceptibility of Candida species isolated from patients with candidemia in southern Taiwan, 2007-2012: impact of new antifungal breakpoints.
    Chen YC; Kuo SF; Chen FJ; Lee CH
    Mycoses; 2017 Feb; 60(2):89-95. PubMed ID: 27621210
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical characteristics of candidaemia in adults with haematological malignancy, and antimicrobial susceptibilities of the isolates at a medical centre in Taiwan, 2001-2010.
    Chen CY; Huang SY; Tsay W; Yao M; Tang JL; Ko BS; Chou WC; Tien HF; Hsueh PR
    Int J Antimicrob Agents; 2012 Dec; 40(6):533-8. PubMed ID: 23006521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes by
    Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
    Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
    Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
    J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidemiological changes with potential implication for antifungal prescription recommendations for fungaemia: data from a nationwide fungaemia surveillance programme.
    Arendrup MC; Dzajic E; Jensen RH; Johansen HK; Kjaeldgaard P; Knudsen JD; Kristensen L; Leitz C; Lemming LE; Nielsen L; Olesen B; Rosenvinge FS; Røder BL; Schønheyder HC
    Clin Microbiol Infect; 2013 Aug; 19(8):E343-53. PubMed ID: 23607326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of Candida spp. isolates: Identification and echinocandin susceptibility in isolates obtained from blood cultures in 15 hospitals in Medellín, Colombia.
    Berrio I; Maldonado N; De Bedout C; Arango K; Cano LE; Valencia Y; Jiménez-Ortigosa C; Perlin DS; Gómez BL; Robledo C; Robledo J;
    J Glob Antimicrob Resist; 2018 Jun; 13():254-260. PubMed ID: 29183771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.